Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (NASDAQ: TLSA) announced the submission of a patent application for the nasal administration of Foralumab, an anti-CD3 monoclonal antibody, as a treatment for COVID-19. This innovative method could enhance immune response and reduce cytokine storms in patients. The company also reported successful Phase 1 trials for both nasal and oral administrations of Foralumab, which showed positive immunomodulatory effects and no severe toxicities. Tiziana holds exclusive rights for this delivery method, aligning with its focus on advancing immunotherapeutic approaches to treat various diseases.
Tiziana Life Sciences plc announced its intention to apply for a standard listing of its ordinary shares on the Official List and admission to trading on the London Stock Exchange's main market. The directors believe this move will enhance the company's global profile, increase trading liquidity, and attract a broader base of investors. Importantly, the company will not issue new shares or raise capital through this listing. A formal notice regarding the cancellation of trading on the AIM market will follow, with expectations to publish a prospectus by late Q3 or early Q4 2020.
Tiziana Life Sciences (Nasdaq: TLSA) announced an investor webinar on July 30, 2020, at 4:00 p.m. U.S. Eastern, where CEO Kunwar Shailubhai will discuss the company’s development pipeline and milestones. The webinar includes a live Q&A session. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases. Key products include TZLS-501, a monoclonal antibody for COVID-19 treatment, and Foralumab, a fully human anti-CD3 mAb aimed at autoimmune diseases.
Tiziana Life Sciences (TLSA), a biotechnology firm, has issued 88,580 new ordinary shares at 93 pence each through the exercise of warrants, generating £82,379 in cash. These shares will be admitted to trading on AIM around July 30, 2020, bringing the total number of ordinary shares to 166,497,593. The new shares rank pari passu with existing shares. Tiziana focuses on developing therapies for oncology, inflammation, and infectious diseases, including its work on Foralumab, an anti-CD3 monoclonal antibody.
Tiziana Life Sciences (Nasdaq: TLSA) announced the appointment of John Brancaccio as a Non-executive Director. With extensive experience in finance within the pharmaceutical and biotechnology sectors, Brancaccio has held significant roles, including CFO positions at various companies. He currently serves on the boards of multiple firms, including Cardiff Oncology, Inc. This appointment comes as Tiziana prepares to advance its clinical programs, including phase 2 studies for its novel treatment for autoimmune diseases, indicating the company's focus on enhancing its leadership team to support future growth.
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) announced that all resolutions were passed at its Annual General Meeting held on July 16, 2020. The meeting took place at 10:00 a.m. in London and New York. The results of the proxy voting will be made available on the Company’s website. Tiziana focuses on discovering and developing novel therapeutic molecules for oncology and immunology, including milciclib and foralumab, a fully human anti-CD3 monoclonal antibody currently in clinical development for various autoimmune and inflammatory diseases.
Tiziana Life Sciences (NASDAQ: TLSA) has submitted a patent application for Foralumab, a fully human anti-CD3 monoclonal antibody, aimed at enhancing CAR-T therapy's effectiveness for cancer and other diseases. The application presents methods to improve CAR-T expansion and survival either alone or with other co-stimulatory agents. Foralumab's reduced cytokine release may improve safety profiles in T-cell therapies. The company is advancing Foralumab for Crohn's Disease and progressive multiple sclerosis, as well as developing an anti-IL-6 receptor monoclonal antibody for COVID-19 treatment.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced a change in its sponsored Level 3 American Depositary Receipt (ADR) programme. ADR holders will receive 1.5 additional ADRs for each existing ADR held as of the record date, July 27, 2020, instead of the previously stated 2.5. Existing ADRs remain valid without requiring exchange. The register at JPMorgan will close for issuances and cancellations from July 27, 2020, and will reopen on August 4, 2020. Tiziana focuses on developing novel molecules to treat diseases including oncology and autoimmunity.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced a ratio change in its sponsored Level 3 American Depositary Receipt (ADR) program, transitioning to a 2.5 for 1 forward split. This adjustment, effective July 31, 2020, alters the ratio from five ordinary shares for one ADR to two ordinary shares per ADR. The change will increase the number of ADSs without affecting the underlying shares or their nominal values. Existing ADR holders will receive 2.5 additional ADRs for each ADR held as of July 27, 2020, the record date.
Tiziana Life Sciences (TLSA) announced an upcoming interview with CEO Kunwar Shailubhai on The RedChip Money Report scheduled for July 12, 2020. The interview will discuss the company's development pipeline and milestones, airing on Bloomberg International and other US channels. Tiziana focuses on innovative treatments for cancer and autoimmune diseases, including Foralumab, a monoclonal antibody in clinical development. The company cautions that forward-looking statements are subject to risks and uncertainties that may affect actual results.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
